Encouraged by the finding that ERBB2 blockade enhances MHC-I induced T cell-mediated killing of SCLC cells, we sought to investigate the impact of ERBB2 and anti-PD-1 on the tumor immune cell compartment applying scRNA-seq in an autochthonous mouse model of SCLC. Here, ERBB2 is linked to small cell lung carcinoma.